Surgical net sales, which include implantables, consumables and equipment/other, were $1.5 billion, an increase of 10% on a reported basis and 6% on a constant currency basis versus the first quarter ...

Alcon () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smarter, ...

Alcon ( (CH:ALC)) has shared an update. On May 5, 2026, Alcon reported first-quarter 2026 results showing net sales of $2.7 billion, up 10% year-on-year on a reported basis and 6% in constant currency ...

Alcon’s ALC Vision Care business continues to gain from its diverse portfolio of contact lenses and ocular health products. Growth momentum within the Surgical business is poised to boost the top line ...

Q1 2026 Management View "The first quarter was an important step forward for our new products, demonstrating strong market acceptance and share gains" (CEO & Director David Endicott), adding that ...

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2026. For the first quarter of 2026, sales were $2.7 billion, up 10% on a ...

Recent share performance and business snapshot Alcon (SWX:ALC) has drawn attention after a period where the stock is down about 10% over the past month and about 17% over the past 3 months, while the ...

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control. In a ...

Earnings call Alcon delivered Q1 2026 sales of $2.7B, up 6% YoY, with core operating margin flat at 21.2% and core diluted EPS of $0.85. Management reaffirmed full-year guidance for 5–7% constant ...

Gdansk, May 6 (Reuters) - Swiss-American eye care company Alcon (ALCC.S), opens new tab reported a 10% rise in its quarterly ‌revenue, citing recent product launches as the main drivers. Sign up here.